Other

Anti-obesity drugs fatten Novo Nordisk profits

Danish drugmaker Novo Nordisk reported Thursday a sharp rise in third quarter sales and profits driven by the success of its anti-diabetes and anti-obesity treatments Ozempic and Wegovy.

page 3 from 15